Table 2. Genotyping information and Fisher’s exact tests for association between SNPs and disease status.
| SNP | rs11200638 (HTRA1 promoter SNP) | rs10490924 (LOC387715/ARMS2) | rs1061170 (CFH) |
|---|---|---|---|
| HWE χ2 |
5.37 |
0.702 |
0.116 |
| Genotypic /Allelic test | |||
| GA |
2.05e-8/ 6.94e-11 |
2.36e-9 / 9.83e-12 |
1.14e-6 / 4.80e-7 |
| GA+CNV |
7.86e-7 / 1.33e-8 |
3.97e-7 / 1.92e-8 |
3.98e-3 / 1.31e-3 |
| CNV |
9.82e-15 / 1.67e-17 |
6.39e-16 / 2.42e-17 |
9.60e-6 / 1.96e-6 |
| Pooled cases |
2.70e-17 / 7.55e-21 |
3.12e-17 / 1.10e-19 |
4.78e-8 / 1.52e-8 |
| Odd Ratio (95% CI) | 3.973 (2.928, 5.390) | 4.671 (3.245, 6.722) | 2.399 (1.768, 3.256) |
Genotyping data confirming Hardy-Weinberg equilibrium for all SNPs analyzed. Fisher’s exact tests shows strong association between SNPs and advanced AMD disease status. Abbreviations: HWE=Hardy–Weinberg Equilibrium. Fisher’s exact genotypic / allelic association test for various disease status: p-value. GA=geographic atrophy, CNV=choroidal neovascularization, GA+CNV refers to those individuals with GA and CNV in one or both eyes.